Infinity Pharmaceuticals, Inc. (INFI): Upgrade News

INFI – Wells Fargo raises to outperform. Stock price at the time of this analyst call was $1.67.


Update: As of Oct. 17, 2017, this bullish analyst call has returned 61.68%.


Key Facts Surrounding This News Item


  • INFI had a POWR Rating of D (Sell) coming into today.
  • INFI was 20.75% above its 10-Day Moving Average coming into today.
  • INFI was 29.66% above its 20-Day Moving Average coming into today.
  • INFI was 40.05% above its 50-Day Moving Average coming into today.
  • INFI was 18.28% above its 100-Day Moving Average coming into today.
  • INFI was -9.54% below its 200-Day Moving Average coming into today.
  • INFI had returned +23.70% year-to-date leading up to today’s news, versus a +15.71% return from the benchmark S&P 500 during the same period.

More Info About Infinity Pharmaceuticals, Inc. (INFI)


Infinity Pharmaceuticals, Inc. discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. The company was founded in 2001 and is based in Cambridge, Massachusetts. View our full INFI ticker page with ratings, news, and more.

INFI at a Glance

INFI Current POWR Rating™
Overall POWR Rating™
INFI Current Price $2.70 8.47%
More INFI Ratings, Data, and News

INFI Price Reaction

The day of this event (Oct. 12, 2017)
INFI Closing Price$3.73 123.35%
INFI Volume61,230,500
7,058.58% from avg
Leading up to this event
INFI 1-mo return39.17%
After this event
INFI 1-day return42.41%
INFI 3-day return38.15%

INFI Price Chart



More Infinity Pharmaceuticals, Inc. (INFI) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All INFI News
Page generated in 0.7395 seconds.